Sign in

Research summary ·

Immune Thrombocytopenia in Low- and Middle-Income Countries: A Systematic Review.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This review looked at adults with ITP in low- and middle-income countries. ITP is an immune problem that affects platelets. Most past research on it comes from rich countries, and may not carry over. The team searched for studies on adults with ITP in these countries. They gathered data on how common it was, infections, treatment and patient views.

What they found

ITP often showed up in younger adults than in rich countries. A large share were secondary ITP, often tied to Helicobacter pylori, hepatitis C or HIV. Corticosteroids were still the usual first drug, but given for long periods. Newer drugs were scarce, so later care often used azathioprine, dapsone, anti-D or spleen removal. Patient reports suggested ITP may greatly affect daily life, work, mood and treatment load.

What it means for patients

The authors say ITP in these countries is shaped by its own factors. They say tests and treatment plans need to fit local resources.

Why it is not certain yet

Most studies were done at a single center. They were observational, so researchers only watched patients. The authors judged most of them at moderate risk of bias. The abstract does not give how many people took part. A review can only be as good as the studies in it.

Source

Immune Thrombocytopenia in Low- and Middle-Income Countries: A Systematic Review.

PubMed · PMID 42911798

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Immune thrombocytopenia (ITP) publications